39 completed, 12 recruiting, 8 withdrawn, 7 terminated. 77 Phase 2, 10 Phase 3, 8 Phase 1.
Follow PTSD: new trials by email Literature Review of PTSD trials Research Report on PTSD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies Transcranial Magnetic Stimulation, Psilocybin (drug), Neurofeedback - PTSD, PTSD - Post Traumatic Stress Disorder | Phase 2 | Not yet recruiting | University of New Mexico | 150 | 2026-12-31 | 2026-10-30 |
| Clinical Trial of MDMA-Assisted Therapy for Military Service Members With Posttraumatic Stress Disorder TREATMENT ARM: Full dose, CONTROL ARM: Active-controlled - PTSD, Post Traumatic Stress Disorder PTSD | Phase 2 | Not yet recruiting | U.S. Army Medical Research and Development Command | 86 | 2026-10-01 | 2026-07-15 |
| Hyperbaric Oxygen Therapy for Veterans With TBI and PCS: A Biomarker Study Hyperbaric Oxygen Therapy (HBOT) - Traumatic Brain Injury (TBI) Patients, Post Concussive Symptoms | Phase 2 | Recruiting | Summit Hyperbarics and Wellness | 34 | 2026-10-01 | 2026-09-30 |
| Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder COMP360 psilocybin - PTSD - Post Traumatic Stress Disorder, PTSD | Phase 2 / Phase 3 | Recruiting | COMPASS Pathways | 300 | 2026-09-01 | 2026-10-23 |
| Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery Cannabidiol (CBD) only, Placebo only, Delta-9-tetrahydrocannabinol (THC) only - PTSD, Post Traumatic Stress Disorder | Phase 1 / Phase 2 | Not yet recruiting | Leslie Lundahl | 280 | 2026-09-01 | 2026-08-26 |
| The Efficacy of a Pharmacological Treatment (Reboxetine Plus Ritalin) Versus Dog-Assisted Therapy in PTSD methylphenidate (Ritalin®), Reboxetine, Placebo - PTSD, Posttraumatic Stress Disorder | Phase 2 | Recruiting | University of Haifa | 160 | 2026-08-01 | 2026-08-18 |
| Psilocybin-Assisted Therapy psilocybin, Supportive Therapy, Prolonged Exposure Therapy - PTSD | Phase 2 | Recruiting | Emory University | 150 | 2026-06-08 | 2026-10-01 |
| Safety and Efficacy of HB-1 for Post-Traumatic Stress Disorder HB-1, Placebo - PTSD, Mental Illness | Phase 2 | Recruiting | HB BioTech, LLC | 200 | 2026-06-03 | 2026-09-24 |
| Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD Psilocybin - Post Traumatic Stress Disorder, PTSD | Phase 2 | Active not recruiting | Unity Health Toronto | 15 | 2026-06-01 | 2026-10-06 |
| Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD Psilocybin 25 mg - Post Traumatic Stress Disorder, PTSD | Phase 2 | Recruiting | Sunstone Medical | 70 | 2026-05-23 | 2026-07-01 |
| Group vs Individual MDMA-Assisted Therapy for PTSD After the October 7, 2023 Events MDMA HCl - PTSD | Phase 2 | Recruiting | Sheba Medical Center | 168 | 2025-12-24 | 2026-03-13 |
| Determining the Potential for Efficacy of OTX-601 in Reducing PTSD Symptoms OTX-601 Digital Therapeutic, OTX-003 Comparator app - PTSD, Post Traumatic Stress Disorder | Phase 2 | Active not recruiting | Oui Therapeutics, Inc. | 40 | 2025-12-09 | 2026-07-15 |
| Induction of Dreaming With EEG and Anesthesia for Post-traumatic Stress Disorder Propofol - PTSD, Post-traumatic Stress Disorder | Phase 2 | Recruiting | Stanford University | 42 | 2025-07-21 | 2026-10-02 |
| PsiloStudy: Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD) Psilocybin 25 mg, Maltodextrin (Placebo) - Alcohol Use Disorder (AUD), PTSD | Phase 2 | Active not recruiting | Nathan Brashares Sackett | 40 | 2025-06-01 | 2026-08-13 |
| MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder MDMA, Cognitive Processing Therapy, MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT) - PTSD | Phase 2 | Recruiting | Patricia Suppes | 30 | 2025-02-10 | 2025-07-31 |
| State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma Psilocybin 15mg, Psilocybin 25mg - PTSD | Phase 2 | Recruiting | Baylor College of Medicine | 15 | 2025-01-30 | 2026-01-22 |
| Intranasal Insulin for Posttraumatic Stress Disorder Intranasal insulin, Placebo - PTSD | Phase 2 | Completed | VA Connecticut Healthcare System | 10 | 2024-10-31 | 2026-07-13 |
| Ultrasonic Neuromodulation for Treatment of PTSD Diadem - PTSD | Phase 1 / Phase 2 | Terminated | University of Utah | 10 | 2024-04-05 | 2025-05-25 |
| MDMA Plus Exposure Therapy for PTSD MDMA - PTSD | Phase 2 | Enrolling by invitation | Emory University | 40 | 2024-02-13 | 2026-07-08 |
| Connectivity Changes Associated With Ketamine Assisted Psychotherapy for PTSD Ketamine Hydrochloride - PTSD | Phase 1 / Phase 2 | Withdrawn | University of New Mexico | 2023-12-31 | 2024-03-12 |
Showing 20 of 77. Sign in to see all of them.
Stress Disorders, Post-Traumatic (77) · Alcoholism (7) · Wounds and Injuries (4) · Combat Disorders (3) · Mental Disorders (3) · Anxiety Disorders (2) · Behavior, Addictive (2) · Depression (2) · Hepatitis C (2) · Psychological Well-Being (2) · Trauma and Stressor Related Disorders (2) · Acquired Immunodeficiency Syndrome (1) · Brain Injuries, Traumatic (1) · Consciousness Disorders (1) · Depressive Disorder, Major (1)
Stress Disorders, Traumatic (76) · Trauma and Stressor Related Disorders (75) · Mental Disorders (74) · Behavior (8) · Chemically-Induced Disorders (8) · Alcohol-Related Disorders (7) · Substance-Related Disorders (7) · Behavioral Symptoms (4) · Nervous System Diseases (4) · Blood-Borne Infections (3) · Communicable Diseases (3) · Infections (3) · RNA Virus Infections (3) · Virus Diseases (3) · Brain Diseases (2)
N-Methyl-3,4-methylenedioxyamphetamine (8) · Psilocybin (8) · Ketamine (6) · Sodium Chloride (5) · Midazolam (4) · Oxytocin (4) · Cycloserine (3) · Therapeutics (3) · Cannabidiol (2) · Cognitive Behavioral Therapy (2) · Methylphenidate (2) · Psychotherapy (2) · glecaprevir and pibrentasvir (2) · 7-oxodehydroepiandrosterone (1) · Acetylcysteine (1)
VA Office of Research and Development (8) · Medical University of South Carolina (4) · Resilient Pharmaceuticals (3) · Tonix Pharmaceuticals, Inc. (3) · UConn Health (3) · Baylor College of Medicine (2) · Emory University (2) · Ohio State University (2) · Stanford University (2) · Tulane University School of Medicine (2) · University of New Mexico (2) · VA Connecticut Healthcare System (2) · White River Junction Veterans Affairs Medical Center (2) · Yale University (2) · Adriana Feder (1)
United States (59) · Canada (3) · Israel (3) · United Kingdom (3) · Australia (2) · Czechia (1) · Germany (1) · Kenya (1) · Netherlands (1) · Norway (1)
Adriana Feder, MD (2) · Bradley V Watts, MD, MPH (2) · Christine E Marx, MD, MA (2) · Denise Bedoya (2) · Ismene L Petrakis, MD (2) · Julian Ford, Ph.D. (2) · Michael S Scheeringa, MD, MPH (2) · Alan K Davis, PhD (1) · Alicia Heapy, Ph.D. (1) · Alina Gonzalez-Mayo, MD (1) · Ann Rasmusson, MD (1) · Anna Wise, PhD (1) · Avi Avital, PhD (1) · Barbara O Rothbaum, PhD (1) · Boris D Heifets, MD, PhD (1)
PMID 24506079, PMID 28569390, PMID 21194898, PMID 24368465, PMID 24740528, PMID 26515712, PMID 27459380, PMID 27678169, PMID 27736051, PMID 28667510, PMID 28682105, PMID 29294429, PMID 31017639, PMID 32521096, PMID 32557843, PMID 32561468, PMID 32608505, PMID 32673006, PMID 33113596, PMID 33979763, PMID 34455213, PMID 34941354, PMID 36405923, PMID 36646315, PMID 37142308, PMID 37384482, PMID 38767196, PMID 39823496, PMID 39895858, PMID 40215385, PMID 41015488, PMID 41947855, PMID 41981270, PMID 42409408, PMID 42533157
1RC1AA019019-01 (1), 1RC1MH088969-01 (1), I01CX001789 (1), I01CX001917 (1), IK2CX002104 (1), K23AA015707 (1), R33MH108753 (1), R44MH136888 (1)